Direkt zum Inhalt
Merck

M-106

Supelco

Mycophenolic acid solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C17H20O6
CAS-Nummer:
Molekulargewicht:
320.34
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

certified reference material

Qualitätsniveau

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

1.0 mg/mL in acetonitrile

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

clinical testing

Format

single component solution

Lagertemp.

−70°C

SMILES String

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O

InChI

1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+

InChIKey

HPNSFSBZBAHARI-RUDMXATFSA-N

Angaben zum Gen

Allgemeine Beschreibung

Assayed in therapeutic drug monitoring to ensure patients remain within the drug′s therapeutic range, mycophenolic acid is an immunosuppressant drug and the active metabolite of the prodrug mycophenolate mofetil. This analytical standard is suitable for LC-MS/MS applications including therapeutic drug monitoring and other clinical or diagnostic applications.

Anwendung


  • Targeted Inhibition in Gastrointestinal Toxicity: Mycophenolic acid is employed in targeted inhibition studies of gut bacterial β-glucuronidases to alleviate gastrointestinal toxicity caused by mycophenolate mofetil. This application is crucial for enhancing patient outcomes in immunosuppressive treatments, showcasing its value in pharmaceutical research (Xia et al., 2024).

  • Synergistic Immunosuppression Therapy: The solution′s use in combination with low dose systemic immunosuppression to sustain vascularized composite allograft survival highlights its potential in transplant medicine. This research underscores the critical role of mycophenolic acid in developing effective immunosuppressive protocols (Feturi et al., 2024).

  • Development of Genetic Markers: Mycophenolic acid′s biochemical properties are utilized in the development of genetic markers within Yarrowia lipolytica, demonstrating its importance in genetic engineering and biotechnological advancements (Zhu et al., 2024).

  • Fungicidal Compound Discovery: The compound is used to derive fungicidal hydrazide lead compounds from sinapic acid and mycophenolic acid, illustrating its application in agricultural biochemistry and the development of new antimicrobial agents (Fang et al., 2023).

Angaben zur Herstellung

This product contains an ampule of 1 mL, at a concentration of 1.0 mg/mL in acetonitrile.

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Piktogramme

FlameExclamation mark

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2 - Flam. Liq. 2

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 2

Flammpunkt (°F)

35.6 °F - closed cup

Flammpunkt (°C)

2 °C - closed cup


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

CD25 blockade for refractory polymyositis.
Nicolò Pipitone et al.
Clinical and experimental rheumatology, 31(3), 474-474 (2013-03-08)
David Wofsy et al.
Arthritis and rheumatism, 65(6), 1586-1591 (2013-03-27)
Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end-stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a
Mycophenolate mofetil in severe lupus nephritis: should post hoc analyses change treatment patterns?
Jonathan J Hogan et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(5), 692-693 (2013-04-16)
E Kieslichova et al.
Transplantation proceedings, 45(2), 770-777 (2013-03-19)
The diagnosis of sepsis is difficult in immunocompromised patients owing to their modified response to infection. Our experiment in minipigs was designed to compare responses to sepsis between experimental groups of septic minipigs with and without immunosuppression. Minipigs with identical
L25. Medical treatment of subglottic stenosis in granulomatosis with polyangiitis (Wegener's).
Paul A Monach
Presse medicale (Paris, France : 1983), 42(4 Pt 2), 575-576 (2013-03-05)

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.